Enrolment completed for pivotal validation study of LungLB®

23 May 2023

LungLife AI, Inc.
(the “Company” or “LungLife”) 

Enrolment completed for pivotal validation study of LungLB®

Company to work with clinical sites to ensure data quality ahead of analysis and readout

 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the completion of enrolment for its prospective, pivotal validation study of LungLB®. Since February 2022, 425 study participants have been enrolled from seventeen sites across the United States from leading academic medical centres and Veterans Affairs hospitals.

The Company is now focused on preparing the data for detailed analysis, including working with each clinical site to finalise monitoring of study data before it is unblinded. Monitoring ensures complete, accurate, and high-quality information will be received for all participants in the study prior to final analyses and results interpretation. In line with expectations, the Company estimates this process will take between 3-4 months, at which point the study results are expected to be known. Following this, the Company will seek to publish the study findings in a peer-reviewed medical journal.

Commenting, Paul Pagano, Chief Executive Officer of LungLife, said: “Completing enrolment is a considerable milestone along the path to commercialisation, and we are pleased that we continue to remain on-track with the timeline set out at IPO. We would like to thank our clinical investigators and their teams, and importantly the study participants, for taking part in our trial and for their continued support with study close-out.”

Click HERE for the full announcement.